CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD DisclosureITEM 7.01.REGULATION FD DISCLOSURE.
On August 3, 2017, the Company issued a press release entitled "Chembio to Host Conference Call to Discuss Second Quarter 2017 Financial Results". A copy of the press release is furnished herewith as Exhibit99.1.
The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.
ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS
Press Release entitled "Chembio to Host Conference Call to Discuss Second Quarter 2017 Financial Results" dated August 3, 2017.
CHEMBIO DIAGNOSTICS, INC. ExhibitEX-99.1 2 ex99_1.htm EXHIBIT 99.1 FOR PRESS RELEASE Chembio to Host Conference Call to Discuss Second Quarter 2017 Financial Results Conference Call Scheduled for Wednesday,…To view the full exhibit click
About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)
Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.